{"id":"NCT01863732","sponsor":"Novartis Pharmaceuticals","briefTitle":"Extension in AS: Sustainability of Benefits, Safety and Tolerability","officialTitle":"An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-06","primaryCompletion":"2018-03-16","completion":"2018-03-16","firstPosted":"2013-05-29","resultsPosted":"2019-07-30","lastUpdate":"2019-07-30"},"enrollment":274,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Spondylitis, Ankylosing"],"interventions":[{"type":"BIOLOGICAL","name":"Secukinumab","otherNames":["AIN457"]},{"type":"OTHER","name":"Placebo (Pbo)","otherNames":[]}],"arms":[{"label":"Secukinumab (AIN457) 75mg Grp1","type":"EXPERIMENTAL"},{"label":"Secukinumab (AIN457) 75 to 150mg Grp1","type":"EXPERIMENTAL"},{"label":"Secukinumab (AIN457) 150mg Grp2","type":"EXPERIMENTAL"},{"label":"Pbo in Core then AIN457 75mg Grp1","type":"EXPERIMENTAL"},{"label":"Pbo in Core then AIN457 75 to 150mg Grp1","type":"EXPERIMENTAL"},{"label":"Pbo in Core then AIN457 150mg Grp2","type":"EXPERIMENTAL"}],"summary":"This 3-year extension study aims at making available the treatment with secukinumab in prefilled syringes (PFS) to patients with ankylosing spondylitis who took part in phase III study CAIN457F2305, defined as \"core study\", as well as to generate additional data on the sustainability of clinical benefits, safety and tolerability during long-term administration of secukinumab.","primaryOutcome":{"measure":"Assessment of Spondyloarthritis International Society Criteria (ASAS) 20 Response From Week 104 to Week 260","timeFrame":"Week 104 to Week 260","effectByArm":[{"arm":"Secukinumab (AIN457) 75mg Group 1","deltaMin":71.4,"sd":null},{"arm":"Secukinumab (AIN457) 150mg Group 2","deltaMin":80,"sd":null},{"arm":"Pbo in Core Then AIN457 75mg Group 1","deltaMin":78.6,"sd":null},{"arm":"Pbo in Core Then AIN457 150mg Group 2","deltaMin":73,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":56,"countries":["United States","Belgium","Bulgaria","Canada","France","Germany","Italy","Mexico","Netherlands","Peru","Russia","Taiwan","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["33351179","33324394","33227175","31565244","30590813"],"seeAlso":["http://www.novartisclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":179},"commonTop":["Nasopharyngitis","Diarrhoea","Headache","Upper respiratory tract infection","Influenza"]}}